BACKGROUND: Antiretroviral therapy (ART) adherence predicts HIV disease progression and survival, but its effect on direct health care costs is unclear. OBJECTIVE: To determine the effect of ART adherence on direct health care costs among adults in a resource-limited setting. DESIGN: Cohort study. SETTING: Aid for AIDS, a private-sector disease management program in South Africa. PATIENTS: 6833 HIV-infected adults who started ART between 6 August 2000 and 30 April 2006. MEASUREMENTS: Monthly direct health care costs authorized by Aid for AIDS were averaged over all months. Pharmacy claim adherence, expressed as a percentage, was categorized into quartiles, from 1 (lowest) to 4 (highest). Effects of covariates on monthly total costs were assessed with a 2-step model with logit for probability of nonzero costs and a generalized linear model (GLM). RESULTS: Total mean monthly costs were $370 (SD, $644). Mean monthly costs of ART were $32 (SD, $18); hospitalizations, $151 (SD, $436); consultations, $76 (SD, $66); investigations, $37 (SD, $50); and non-ART medications, $53 (SD, $180). Total mean monthly costs ranged from $313 (SD, $598) for quartile 4 to $376 (SD, $657) for quartile 1. Hospitalization costs increased from 29% to 51% of total costs as adherence decreased. In the GLM 2-step model, moving from adherence quartile 1 to quartile 2, 3, or 4 increased the probability of having nonzero total monthly costs by 0.078, 0.15, and 0.21 percentage point, respectively (P < 0.001). For patients with nonzero costs, increasing adherence from quartile 1 to quartile 2, 3, or 4 decreased total monthly costs by $70, $133, and $192, respectively (P < 0.001). Moving from adherence quartiles 1 to 4 had the highest decrease in net overall median monthly health care costs (-$85 [interquartile range, -$116 to -$41]). LIMITATIONS: Indirect health care costs were not included. Experience may not reflect that of public HIV/AIDS programs. CONCLUSION: High ART adherence was associated with lower mean monthly direct health care costs, particularly reduced hospitalization costs, in this South African HIV cohort.
BACKGROUND: Antiretroviral therapy (ART) adherence predicts HIV disease progression and survival, but its effect on direct health care costs is unclear. OBJECTIVE: To determine the effect of ART adherence on direct health care costs among adults in a resource-limited setting. DESIGN: Cohort study. SETTING: Aid for AIDS, a private-sector disease management program in South Africa. PATIENTS: 6833 HIV-infected adults who started ART between 6 August 2000 and 30 April 2006. MEASUREMENTS: Monthly direct health care costs authorized by Aid for AIDS were averaged over all months. Pharmacy claim adherence, expressed as a percentage, was categorized into quartiles, from 1 (lowest) to 4 (highest). Effects of covariates on monthly total costs were assessed with a 2-step model with logit for probability of nonzero costs and a generalized linear model (GLM). RESULTS: Total mean monthly costs were $370 (SD, $644). Mean monthly costs of ART were $32 (SD, $18); hospitalizations, $151 (SD, $436); consultations, $76 (SD, $66); investigations, $37 (SD, $50); and non-ART medications, $53 (SD, $180). Total mean monthly costs ranged from $313 (SD, $598) for quartile 4 to $376 (SD, $657) for quartile 1. Hospitalization costs increased from 29% to 51% of total costs as adherence decreased. In the GLM 2-step model, moving from adherence quartile 1 to quartile 2, 3, or 4 increased the probability of having nonzero total monthly costs by 0.078, 0.15, and 0.21 percentage point, respectively (P < 0.001). For patients with nonzero costs, increasing adherence from quartile 1 to quartile 2, 3, or 4 decreased total monthly costs by $70, $133, and $192, respectively (P < 0.001). Moving from adherence quartiles 1 to 4 had the highest decrease in net overall median monthly health care costs (-$85 [interquartile range, -$116 to -$41]). LIMITATIONS: Indirect health care costs were not included. Experience may not reflect that of public HIV/AIDS programs. CONCLUSION: High ART adherence was associated with lower mean monthly direct health care costs, particularly reduced hospitalization costs, in this South African HIV cohort.
Authors: Linda Beer; Jennifer L Fagan; Pamela Garland; Eduardo E Valverde; Barbara Bolden; Kathleen A Brady; Maria Courogen; Daniel Hillman; Alan Neaigus; Jeanne Bertolli Journal: AIDS Patient Care STDS Date: 2012-02-09 Impact factor: 5.078
Authors: Krisda Chaiyachati; Lisa R Hirschhorn; Frank Tanser; Marie-Louise Newell; Till Bärnighausen Journal: AIDS Patient Care STDS Date: 2011-01-26 Impact factor: 5.078
Authors: Jacob Bor; Till Bärnighausen; Colin Newell; Frank Tanser; Marie-Louise Newell Journal: Trop Med Int Health Date: 2011-05-26 Impact factor: 2.622
Authors: Jessica E Haberer; Gregory K Robbins; Michele Ybarra; Alexandra Monk; Kathleen Ragland; Sheri D Weiser; Mallory O Johnson; David R Bangsberg Journal: AIDS Behav Date: 2012-02
Authors: Bohdan Nosyk; Viviane Lima; Guillaume Colley; Benita Yip; Robert S Hogg; Julio S G Montaner Journal: Pharmacoeconomics Date: 2015-03 Impact factor: 4.981
Authors: Rory Leisegang; Gary Maartens; Michael Hislop; Leon Regensberg; Susan Cleary Journal: BMC Health Serv Res Date: 2010-07-02 Impact factor: 2.655
Authors: Timothy E Morey; Matthew Booth; Scott Wasdo; Judith Wishin; Brian Quinn; Daniel Gonzalez; Hartmut Derendorf; Susan P McGorray; Jane Simoni; Richard J Melker; Donn M Dennis Journal: AIDS Behav Date: 2013-01